your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Tyrosine kinase inhibitor activity on BCR-ABL1 mutations in chronic myeloid leukemia

Activity of imatinib mesylate and the second generation tyrosine kinase inhibitors nilotinib and dasatinib against a selection of BCR-ABL1 mutants found in patients with CML. All concentrations are shown in nanomoles per milliliter and represent IC₅₀ values.

CML: chronic myeloid leukemia; TKI: tyrosine kinase inhibitor; NA: not available.

Republished with permission of the American Society of Hematology, from Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619. Copyright © 2009; permission conveyed through Copyright Clearance Center, Inc.

Graphic 109963 Version 4.0